{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T13:59:47Z","timestamp":1794751187541,"version":"4.9.1"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","prd-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.parkreldis.2024.107255","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T16:52:23Z","timestamp":1735059143000},"page":"107255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["The effect of Amyloid and Tau Co-pathology on disease progression in Lewy body dementia: A systematic review"],"prefix":"10.1016","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7257-9195","authenticated-orcid":false,"given":"Jerry HK.","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel AS.","family":"Laurell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Sidhom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2024.107255_bib1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1017\/S0033291713000494","article-title":"The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies","volume":"44","author":"Vann Jones","year":"2014","journal-title":"Psychol. Med."},{"key":"10.1016\/j.parkreldis.2024.107255_bib2","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1212\/WNL.47.5.1113","article-title":"Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop","volume":"47","author":"McKeith","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2024.107255_bib3","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Dementia with Lewy bodies: diagnosis and management: third report of the DLB Consortium","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2024.107255_bib4","author":"McKeith"},{"key":"10.1016\/j.parkreldis.2024.107255_bib5","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/jnc.14698","article-title":"Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies \u2013 current issues and future directions","volume":"150","author":"Walker","year":"2019","journal-title":"J. Neurochem."},{"key":"10.1016\/j.parkreldis.2024.107255_bib6","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1093\/brain\/awy146","article-title":"Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated","volume":"141","author":"Robinson","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2024.107255_bib7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1001\/jamaneurol.2016.4926","article-title":"Duration and pathologic correlates of lewy body disease","volume":"74","author":"Graff-Radford","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.parkreldis.2024.107255_bib8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","article-title":"Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis","volume":"16","author":"Irwin","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2024.107255_bib9","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.parkreldis.2020.09.030","article-title":"Prevalence and clinical associations of tau in Lewy body dementias: a systematic review and meta-analysis","volume":"80","author":"Chin","year":"2020","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.parkreldis.2024.107255_bib10","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/mds.26191","article-title":"Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review","volume":"30","author":"Petrou","year":"2015","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.parkreldis.2024.107255_bib11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jamaneurol.2021.5216","article-title":"Amyloid biomarker study group, prevalence estimates of amyloid abnormality across the alzheimer disease clinical spectrum","volume":"79","author":"Jansen","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.parkreldis.2024.107255_bib12","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.neurobiolaging.2020.11.006","article-title":"Imaging tau burden in dementia with Lewy bodies using [18F]-AV1451 positron emission tomography","volume":"101","author":"Mak","year":"2021","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.parkreldis.2024.107255_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2020.102333","article-title":"The combined effect of amyloid-beta and tau biomarkers on brain atrophy in dementia with Lewy bodies","volume":"27","author":"Abdelnour","year":"2020","journal-title":"NeuroImage Clin"},{"key":"10.1016\/j.parkreldis.2024.107255_bib14","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/mds.26668","article-title":"Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia","volume":"31","author":"Abdelnour","year":"2016","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.parkreldis.2024.107255_bib15","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/gps.2496","article-title":"The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia","volume":"26","author":"Andersson","year":"2011","journal-title":"Int. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.parkreldis.2024.107255_bib16","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jagp.2019.12.009","article-title":"Amyloid imaging and longitudinal clinical progression in dementia with lewy bodies","volume":"28","author":"Donaghy","year":"2020","journal-title":"Am. J. Geriatr. Psychiatry Off. J. Am. Assoc. Geriatr. Psychiatry"},{"key":"10.1016\/j.parkreldis.2024.107255_bib17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13195-019-0537-5","article-title":"Amyloid-beta peptides in cerebrospinal fluid of patients with dementia with Lewy bodies","volume":"11","author":"van Steenoven","year":"2019","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.parkreldis.2024.107255_bib18","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1192\/bjp.2023.166","article-title":"Estimating demand for potential disease-modifying therapies for Alzheimer's disease in the UK","volume":"224","author":"Laurell","year":"2024","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.parkreldis.2024.107255_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14039","article-title":"In vivo detection of Alzheimer's and Lewy body disease concurrence: clinical implications and future perspectives","author":"Baiardi","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.parkreldis.2024.107255_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awae203","article-title":"Clinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease","author":"Barba","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2024.107255_bib21","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/alz.12814","article-title":"The ISTAART Lewy body dementias Trial Methods Working Group, Dementia with Lewy bodies: impact of co-pathologies and implications for clinical trial design","volume":"19","author":"Toledo","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.parkreldis.2024.107255_bib22","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1007\/s13311-023-01379-z","article-title":"Fluid and biopsy based biomarkers in Parkinson's disease","volume":"20","author":"Coughlin","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.parkreldis.2024.107255_bib23","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/mds.27355","article-title":"Biomarkers for cognitive impairment in Lewy body disorders: status and relevance for clinical trials","volume":"33","author":"Siderowf","year":"2018","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.parkreldis.2024.107255_bib24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/mds.27867","article-title":"Pathological influences on clinical heterogeneity in lewy body diseases","volume":"35","author":"Coughlin","year":"2020","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.parkreldis.2024.107255_bib25","doi-asserted-by":"crossref","first-page":"e476","DOI":"10.1212\/WNL.0000000000007855","article-title":"Neuropathologic correlates of amyloid and dopamine transporter imaging in Lewy body disease","volume":"93","author":"Shirvan","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2024.107255_bib26","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/gps.3881","article-title":"Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies","volume":"28","author":"Brunnstrom","year":"2013","journal-title":"Int. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.parkreldis.2024.107255_bib27","doi-asserted-by":"crossref","first-page":"e1038","DOI":"10.1212\/WNL.0000000000005166","article-title":"CSF tau and beta-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders","volume":"90","author":"Irwin","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2024.107255_bib28","article-title":"Clinical application of CSF biomarkers for Alzheimer's disease: from rationale to ratios, Alzheimers Dement","volume":"14","author":"Bouwman","year":"2022","journal-title":"Diagn. Assess. Dis. Monit."},{"key":"10.1016\/j.parkreldis.2024.107255_bib29","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers","volume":"12","author":"Jack","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2024.107255_bib30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for alzheimer disease pathology","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.parkreldis.2024.107255_bib31","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1016\/j.neuron.2023.05.017","article-title":"Blood-based biomarkers for Alzheimer's disease: current state and future use in a transformed global healthcare landscape","volume":"111","author":"Hampel","year":"2023","journal-title":"Neuron"},{"key":"10.1016\/j.parkreldis.2024.107255_bib32","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.parkreldis.2024.107255_bib33","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"10.1016\/j.parkreldis.2024.107255_bib34","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.parkreldis.2024.107255_bib35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41512-019-0050-0","article-title":"Elaborating on the assessment of the risk of bias in prognostic studies in pain rehabilitation using QUIPS\u2014aspects of interrater agreement","volume":"3","author":"Grooten","year":"2019","journal-title":"Diagn. Progn. Res."},{"key":"10.1016\/j.parkreldis.2024.107255_bib36","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1212\/WNL.53.9.2003","article-title":"Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies","volume":"53","author":"Gomez-Isla","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2024.107255_bib37","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/ana.20635","article-title":"Neuropathology of dementia in Parkinson's disease: a prospective, community-based study","volume":"58","author":"Aarsland","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.parkreldis.2024.107255_bib38","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1212\/01.WNL.0000165987.89198.65","article-title":"Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both","volume":"64","author":"Kraybill","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2024.107255_bib39","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0b013e3181bacf9e","article-title":"Relative preservation of MMSE scores in autopsy-proven dementia with Lewy bodies","volume":"73","author":"Nelson","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2024.107255_bib40","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1001\/archneurol.2012.1608","article-title":"Pathologic accumulation of \u03b1-synuclein and A\u03b2 in Parkinson disease patients with dementia","volume":"69","author":"Kotzbauer","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.parkreldis.2024.107255_bib41","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/bpa.12182","article-title":"Regional multiple pathology scores are associated with cognitive decline in L ewy body dementias","volume":"25","author":"Howlett","year":"2015","journal-title":"Brain Pathol."},{"key":"10.1016\/j.parkreldis.2024.107255_bib42","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/bpa.12697","article-title":"Degeneration of dopaminergic circuitry influences depressive symptoms in Lewy body disorders","volume":"29","author":"Patterson","year":"2019","journal-title":"Brain Pathol."},{"key":"10.1016\/j.parkreldis.2024.107255_bib43","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1212\/WNL.0000000000009763","article-title":"Subtypes of dementia with Lewy bodies are associated with alpha-synuclein and tau distribution","volume":"95","author":"Ferman","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2024.107255_bib44","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1002\/mds.23393","article-title":"Amyloid imaging of Lewy body-associated disorders","volume":"25","author":"Foster","year":"2010","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.parkreldis.2024.107255_bib45","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1093\/brain\/aws173","article-title":"Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies","volume":"135","author":"Graff-Radford","year":"2012","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.parkreldis.2024.107255_bib46","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1093\/brain\/aww193","article-title":"Amyloid-beta deposition and regional grey matter atrophy rates in dementia with Lewy bodies","volume":"139","author":"Sarro","year":"2016","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.parkreldis.2024.107255_bib47","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.16439","article-title":"Association of longitudinal beta-amyloid accumulation determined by positron emission tomography with clinical and cognitive decline in adults with probable lewy body dementia","volume":"2","author":"Nedelska","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.parkreldis.2024.107255_bib48","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3233\/JAD-190323","article-title":"Clinical correlates of cerebral amyloid deposition in Parkinson's disease dementia: evidence from a PET study","volume":"70","author":"Palermo","year":"2019","journal-title":"J. Alzheimers Dis. JAD"},{"key":"10.1016\/j.parkreldis.2024.107255_bib49","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/mds.28973","article-title":"Longitudinal tau positron emission tomography in dementia with lewy bodies","volume":"37","author":"Chen","year":"2022","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.parkreldis.2024.107255_bib50","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/brain\/awz311","article-title":"Cognitive fluctuations in Lewy body dementia: towards a pathophysiological framework","volume":"143","author":"Matar","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2024.107255_bib51","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0010-9452(08)70489-1","article-title":"A review of cognitive impairments in dementia with lewy bodies relative to Alzheimer's disease and Parkinson's disease with dementia","volume":"43","author":"Metzler-Baddeley","year":"2007","journal-title":"Cortex"},{"key":"10.1016\/j.parkreldis.2024.107255_bib52","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000249145","article-title":"Cerebrospinal fluid total tau is associated with shorter survival in dementia with Lewy bodies","volume":"28","author":"Bostrom","year":"2009","journal-title":"Dement. Geriatr. Cogn. Disord"},{"key":"10.1016\/j.parkreldis.2024.107255_bib53","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/jnnp-2016-313775","article-title":"Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies","volume":"88","author":"Lemstra","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2024.107255_bib54","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3233\/JAD-210365","article-title":"Genetics contributes to concomitant pathology and clinical presentation in dementia with lewy bodies","volume":"83","author":"van der Lee","year":"2021","journal-title":"J. Alzheimers Dis. JAD"},{"key":"10.1016\/j.parkreldis.2024.107255_bib55","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000200048","article-title":"Association of the ATN research framework with clinical profile, cognitive decline, and mortality in patients with dementia with lewy bodies","volume":"98","author":"Van De Beek","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2024.107255_bib56","doi-asserted-by":"crossref","DOI":"10.1002\/gps.5839","article-title":"Disease progression in dementia with Lewy bodies: a longitudinal study on clinical symptoms, quality of life and functional impairment","volume":"37","author":"van de Beek","year":"2022","journal-title":"Int. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.parkreldis.2024.107255_bib57","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamaneurol.2021.4222","article-title":"Association of plasma p-tau181 and p-tau231 concentrations with cognitive decline in patients with probable dementia with lewy bodies","volume":"79","author":"Gonzalez","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.parkreldis.2024.107255_bib58","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/jnnp-2021-327788","article-title":"Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy","volume":"93","author":"Chouliaras","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2024.107255_bib59","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.parkreldis.2022.07.008","article-title":"The relationship between plasma biomarkers and amyloid PET in dementia with Lewy bodies","volume":"101","author":"Donaghy","year":"2022","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.parkreldis.2024.107255_bib60","doi-asserted-by":"crossref","first-page":"e1708","DOI":"10.1212\/WNL.0000000000207755","article-title":"Association of plasma phosphorylated tau with the response to Neflamapimod treatment in patients with dementia with lewy bodies","volume":"101","author":"Alam","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2024.107255_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/ana.27003","article-title":"Plasma pTau181 reveals a pathological signature that predicts cognitive outcomes in lewy body disease","author":"Abdelnour","year":"2024","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.parkreldis.2024.107255_bib62","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209418","article-title":"For the European-dementia with lewy bodies (E-DLB) consortium, association of plasma amyloid, P-tau, GFAP, and NfL with CSF, clinical, and cognitive features in patients with dementia with lewy bodies","volume":"102","author":"Bolsewig","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2024.107255_bib63","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.trci.2019.06.005","article-title":"Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials, Alzheimers Dement","volume":"5","author":"Andrews","year":"2019","journal-title":"Transl. Res. Clin. Interv."},{"key":"10.1016\/j.parkreldis.2024.107255_bib64","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","article-title":"Cognitive decline in Parkinson disease","volume":"13","author":"Aarsland","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.parkreldis.2024.107255_bib65","first-page":"107","article-title":"Neuropathological and biomarker findings in Parkinson's disease and Alzheimer's disease: from protein aggregates to synaptic dysfunction","volume":"11","author":"Compta","year":"2021","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.parkreldis.2024.107255_bib66","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.parkreldis.2024.107255_bib67","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jagp.2013.03.001","article-title":"Amyloid PET imaging in lewy body disorders","volume":"23","author":"Donaghy","year":"2015","journal-title":"Am. J. Geriatr. Psychiatry Off. J. Am. Assoc. Geriatr. Psychiatry"},{"key":"10.1016\/j.parkreldis.2024.107255_bib68","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/ana.25392","article-title":"Cognitive and pathological influences of tau pathology in lewy body disorders","volume":"85","author":"Coughlin","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.parkreldis.2024.107255_bib69","first-page":"53","article-title":"A systematic review of cognitive decline in dementia with Lewy bodies versus Alzheimer's disease","volume":"6","author":"Breitve","year":"2014","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.parkreldis.2024.107255_bib70","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1212\/WNL.0b013e3181f39a78","article-title":"CSF amyloid (beta) 1-42 predicts cognitive decline in Parkinson disease","volume":"75","author":"Siderowf","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2024.107255_bib71","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.parkreldis.2013.03.009","article-title":"Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study","volume":"19","author":"Compta","year":"2013","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.parkreldis.2024.107255_bib72","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1212\/WNL.0000000000000425","article-title":"CSF A\u03b242 predicts early-onset dementia in Parkinson disease","volume":"82","author":"Alves","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2024.107255_bib73","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41531-021-00247-x","article-title":"Cerebrospinal fluid biomarkers in Parkinson's disease with freezing of gait: an exploratory analysis","volume":"7","author":"Hatcher-Martin","year":"2021","journal-title":"Npj Park. Dis."},{"key":"10.1016\/j.parkreldis.2024.107255_bib74","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1212\/WNL.0000000000006692","article-title":"CSF \u03b2-amyloid(42) and risk of freezing of gait in early Parkinson disease","volume":"92","author":"Kim","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2024.107255_bib75","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/nan.12294","article-title":"Cortical Lewy bodies and Abeta burden are associated with prevalence and timing of dementia in Lewy body diseases","volume":"42","author":"Ruffmann","year":"2016","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.parkreldis.2024.107255_bib76","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1093\/brain\/aws234","article-title":"Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies","volume":"135","author":"Schneider","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2024.107255_bib77","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/s41591-023-02449-7","article-title":"Clinical effects of Lewy body pathology in cognitively impaired individuals","volume":"29","author":"Quadalti","year":"2023","journal-title":"Nat. Med."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802024012677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802024012677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T11:12:26Z","timestamp":1737630746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802024012677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":77,"alternative-id":["S1353802024012677"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2024.107255","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of Amyloid and Tau Co-pathology on disease progression in Lewy body dementia: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2024.107255","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107255"}}